A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC)

被引：19

作者：

Zhu, A. X.

Finn, R. S.

Mulcahy, M. F.

Gurtler, J. S.

Sun, W.

Schwartz, J. D.

Rojas, P.

Dontabhaktuni, A.

Youssoufian, H.

Stuart, K. E.

机构：

[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA

[2] Univ Calif Los Angeles, Los Angeles, CA USA

[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[4] East Jefferson Gen Hosp, Metairie, LA USA

[5] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[6] ImClone Syst, Branchburg, NJ USA

[7] Tufts Univ, Sch Med, Lahey Clin Med Ctr, Burlington, MA USA

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.4083

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4083

引用

页数：1